When a founder with a £200 million track record doubles down on his own company, smart investors take notice. Professor Sir Chris Evans has just led a rapid-fire £3 million raise for EDX Medical, a Cambridge-based medtech firm with a breakthrough prostate cancer test—and his confidence is as telling as the technology.
EDX Medical, founded in 2021 and listed on Aquis, has secured £3 million in fresh funding to accelerate the commercial development of its cutting-edge diagnostic pipeline. At the centre of this raise is Evans himself, who invested £740,000 to acquire 5.3 million shares, boosting his stake to 36.6%. Joining him in this strong vote of confidence were CEO Dr Mike Hudson and Deputy Chair Martin Walton, who each subscribed for over 60,000 shares.
Evans expressed his satisfaction with the support from both new and returning investors, noting their enthusiasm for the company’s mission to deliver high-quality diagnostic solutions—starting with a revolutionary prostate cancer test. This test, described as a ‘super test’, analyses both blood and urine samples using prostate-specific biomarkers. These are interpreted via a proprietary AI algorithm to identify and characterise signs of cancer with precision.
This funding injection will enable EDX to fast-track the scale-up and production of this flagship test, alongside other innovative diagnostics in the pipeline. The strong investor appetite, particularly given the speed of the raise, suggests rising momentum behind the company’s clinical and commercial potential.
Professor Sir Chris Evans, widely regarded as one of the UK’s most successful biotech entrepreneurs, has founded over 50 companies, including more than 20 that have reached the public markets. His latest backing of EDX Medical sends a clear message: this is a company to watch.
EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.
